Loading...

VTGN VISTAGEN THERAPEUTICS INC Expansion Plans 8-K Filing

VSTG

VTGN

VISTAGEN THERAPEUTICS INC

(VTGN)

2025 8-K

Summary

Summary

Director Appointment

Management Changes

Financial Statements

Equity Offerings

Product Expansion

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Earnings Report

Filing Letter with Quantita...

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Underwriting Agreement

Quantitative Data

Update on Progress and Fina...

Filing with Quantitative Data

Filing with Quantitative Data

Other Special Situation

Filing Letter with Financia...

Other Special Situation

Filing with Quantitative Data

Financial Update

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Filing with Quantitative Data

Quantitative Data

Other Special Situation

Filing Letter with Quantita...

Other Special Situation

Filing with Quantitative Data

Filing Letter with Quantita...

Update on Clinical Developm...

External Links:

On June 2, 2025, Vistagen Therapeutics provided an update on its clinical trials for fasedienol, announcing expected topline data from the PALISADE-3 trial in Q4 2025 and for PALISADE-4 in the first half of 2026.

AI Assistant

VISTAGEN THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.